Tom was fifty-five and didn’t think he had a problem. LDL at 118 mg/dL. Blood pressure 125/80. He exercised. Wasn’t obese. By every standard metric his physician checked during the annual physical, he landed in the “monitor and maintain” category — keep doing what you’re doing, see you next year. Nobody suggested a coronary artery calcium scan. The test took ten minutes and cost $200 out of pocket. When the results came back, Tom’s CAC score was 487. Stage severe. Significant calcified plaque sitting in three major coronary vessels. His cardiologist told him he had the arteries of a seventy-five-year-old.
Tom started aggressive statin therapy, aspirin, a complete lifestyle overhaul. He didn’t have a heart attack — partly because the scan caught the underlying reality before his cardiovascular system betrayed him during a Saturday morning run.
The coronary artery calcium scan is one of the most powerful, most underused tools in preventive cardiology. Here’s the complete guide: what it measures, what the scores mean, and how to use the information to make better decisions about cardiovascular health.
What a Coronary Calcium Scan Actually Measures
What it specifically measures: calcified atherosclerotic plaque. When LDL particles infiltrate the arterial wall and atherosclerosis progresses, calcium deposits into the plaque over years to decades. This calcification gets directly visualized and quantified by CT. The resulting number — the Agatston score — integrates the density and area of calcium deposits across each major coronary vessel (left anterior descending, right coronary artery, left circumflex, left main) into a single composite figure.
What a CAC scan does not measure: non-calcified (“soft”) plaque, the type most prone to rupture and causing acute heart attacks. An important limitation, this one — a zero CAC score doesn’t mean zero atherosclerosis. It means zero calcified atherosclerosis. Younger patients, particularly under 45-50, with early atherosclerosis may carry significant soft plaque burden without having developed calcification yet. Despite the limitation, the CAC score remains the single most powerful predictor of cardiovascular events available in a non-invasive, relatively cheap test.
The MESA (Multi-Ethnic Study of Atherosclerosis) study, cited comprehensively by Hecht (2015), followed over 6,800 men and women across four ethnic groups for over a decade and showed CAC score predicting cardiovascular events far more powerfully than traditional risk factor models. The predictive value held across all ethnicities and age groups, establishing CAC scoring as the gold standard for cardiovascular risk stratification beyond the standard risk calculators.
The CAC Score Categories: What the Numbers Mean
The Agatston score comes back as a single number, divided into risk categories that guide clinical decision-making. Understanding these categories — and what each implies prognostically — matters for interpreting your own result.
- CAC = 0 (Zero): No calcified plaque detected. This carries profound prognostic significance: a CAC of zero in a patient over 40 associates with a 10-year cardiovascular event rate below 1-2%, regardless of traditional risk factors. Even patients with LDL above 190 mg/dL who score zero have very low near-term risk. The MESA study found 10-year event rates in CAC=0 patients so low — roughly 0.4% annually — that the absolute benefit of statin therapy is minimal, which is why many cardiologists now support a “statin holiday” approach for otherwise intermediate-risk patients who score zero.
- CAC 1-100 (Mild/Early): Some calcified plaque present. Moderate 10-year risk — roughly 3-8% in most populations. This category typically supports starting or intensifying statin therapy if not already on it, and it motivates serious lifestyle change. The specific location of the calcium matters: calcium in the left anterior descending artery (LAD), which supplies the largest territory of heart muscle, carries more prognostic weight than equivalent calcium sitting in smaller vessels.
- CAC 100-400 (Moderate): Significant calcified plaque burden. Ten-year event rates in the 8-15% range. Statin therapy — usually high-intensity — is strongly indicated here. Aspirin may be appropriate depending on full risk assessment and bleeding risk. This is the zone where aggressive multi-modal intervention is most clearly justified: statin, lifestyle, blood pressure control, potentially additional lipid-lowering agents like ezetimibe or a PCSK9 inhibitor.
- CAC > 400 (Severe/Extensive): Very high plaque burden. Ten-year event rates typically above 15-20%. These patients are functionally in a secondary prevention category — their risk resembles someone who’s already had a cardiovascular event. Maximum statin therapy combined with full cardiovascular risk factor optimization is standard. Some cardiologists in this group recommend a stress test or other functional cardiac imaging to see whether any plaque areas are producing significant coronary obstruction.
The percentile ranking relative to age and sex deserves special attention, and some reporting systems provide it (particularly ones using the MESA calculator). A 55-year-old man with a CAC of 150 might sit at the 75th percentile for his age and sex — meaning 75% of men his age score lower. That percentile framing can be more clinically useful than the raw number alone, since it puts the plaque burden in context against biological peers.
Why CAC Outperforms Standard Risk Calculators
The ACC/AHA Pooled Cohort Equations (PCE) and the Framingham Risk Score are the most widely used tools for estimating 10-year cardiovascular risk in clinical practice. They use inputs like age, sex, race, total cholesterol, HDL, systolic blood pressure, diabetes status, and smoking history to generate a probability estimate. Useful for population-level risk stratification. Less useful — well-documented limitations, actually — at the individual level.
The fundamental problem with risk calculators: they estimate the average risk of someone with your demographic and risk factor profile. They don’t know whether your specific arteries have been damaged or spared, whatever your risk factors say. Two 55-year-old men with identical risk factor profiles can carry dramatically different actual atherosclerotic burdens, based on genetic differences in lipid metabolism, inflammatory response, vascular repair capacity, and decades of subtle lifestyle differences no risk calculator captures.
CAC scoring resolves this by directly imaging the end-result of the atherosclerotic process. It doesn’t estimate risk. It measures the biological damage already present. Someone with multiple risk factors but CAC=0 has been “protected” by genetics or behavior despite the risk factors. Someone with few apparent risk factors but CAC above 300 has accumulated significant plaque despite looking low-risk by conventional measures. CAC scanning reclassifies a substantial share of patients in ways that actually change clinical management.
Multiple studies have shown that adding CAC to the standard PCE calculation significantly improves risk discrimination — the statistical measure of how well a model separates people who will and won’t have events. In the MESA study, adding CAC to the PCE C-statistic (a measure of discrimination) improved risk classification by as much as 0.05-0.1, which in clinical terms means correctly reclassifying a substantial proportion of intermediate-risk patients as either high-risk (motivating more aggressive treatment) or low-risk (avoiding unnecessary treatment).
Who Should Get a CAC Scan
Current American College of Cardiology/American Heart Association guidelines recommend considering CAC scoring to guide statin initiation in patients sitting in the “intermediate risk” zone (7.5-20% 10-year risk by PCE) where the statin decision is genuinely uncertain. A zero CAC in this group supports deferring statin therapy; above 100 supports starting it.
Beyond the guideline indications, a broader group could meaningfully benefit from CAC information. The most compelling candidates: men above 45 and women above 55 wanting the most accurate read on their current cardiovascular trajectory; anyone in the intermediate risk zone whose physician is “on the fence” about statin therapy; anyone with a strong family history of premature cardiovascular disease; men between 40-60 who are athletes or exercise extensively (paradoxically, very high exercise volumes have been associated with higher coronary calcium in some studies — not because exercise causes disease, but because exercise exposure and coronary calcium may be independent processes, and high CAC in a competitive athlete changes the risk management picture); and anyone who’s been declining statin therapy based on low risk and wants objective data to support or challenge that call.
The test isn’t particularly useful for the very young (below 40, when calcified plaque is rare even in high-risk individuals), for patients already established in the secondary prevention category (who should be on maximum therapy regardless), or for patients with known severe atherosclerosis where the CAC score won’t change management anyway.
The role of CAC in women deserves specific mention. Women tend to develop coronary calcium roughly a decade later than men, so a zero CAC in a 45-year-old woman carries different implications than in a 60-year-old woman. Risk calculators tend to underestimate cardiovascular risk in some women — particularly those with inflammatory conditions, early menopause, or a history of preeclampsia — making CAC scanning potentially more impactful in identifying the subset of women whose actual plaque burden exceeds what their risk score suggests.
What Causes Coronary Calcium to Progress
Coronary calcium progression isn’t inevitable, and understanding what drives it points toward the interventions most likely to slow it. Multiple factors predict faster CAC progression in longitudinal studies.
Dyslipidemia — particularly high ApoB, high Lp(a), high triglycerides with low HDL — predicts faster plaque accumulation and calcification. LDL-lowering with statins doesn’t halt calcification (and counterintuitively may increase the CAC score while improving plaque stability — more on that below), but reducing ApoB and LDL particle number reduces the rate at which new plaque forms.
Hypertension accelerates coronary calcium progression through the mechanical stress it puts on arterial walls, which promotes endothelial injury and inflammatory infiltration. Every 10 mmHg reduction in systolic blood pressure associates with meaningful reductions in cardiovascular event rates, including events driven by coronary atherosclerosis specifically.
Insulin resistance and diabetes are potent drivers of coronary calcium progression. Glycation of LDL particles, advanced glycation end-products (AGEs), and the inflammatory and oxidative stress environment of hyperglycemia all collectively accelerate every stage of the atherosclerotic process. Optimal glucose control (HbA1c below 5.5%) associates with slower CAC progression than borderline hyperglycemia.
Chronic systemic inflammation, measured by high-sensitivity CRP, is independently associated with CAC progression. One reason the JUPITER trial — which enrolled patients with normal LDL but elevated CRP and treated them with rosuvastatin — showed significant cardiovascular benefit: the statin reduced both LDL and CRP, hitting both the lipid and inflammatory pathways of plaque growth at once.
The Paradox: Statins Can Increase CAC Scores
One of the more counterintuitive findings in preventive cardiology: statin therapy, which clearly reduces cardiovascular events, is associated with increases in CAC score over time. Multiple large observational studies have confirmed patients on statins show faster increases in coronary calcium scores than matched patients not on statins — despite the statins providing clear cardiovascular protection. Sounds backwards. Isn’t.
The mechanistic explanation: statins stabilize existing plaques by promoting calcification within them. Soft, lipid-rich, uncalcified plaques are the dangerous ones — prone to rupture, prone to causing acute heart attacks. Statins appear to calcify and harden these soft plaques, making them more stable even while raising the CAC score. A higher CAC score on statin therapy may actually reflect more stable, not more dangerous, plaque.
The practical implication matters: if you’re on statin therapy and get serial CAC scanning, a modestly increased score doesn’t mean the treatment is failing or the risk is worsening. It may reflect plaque stabilization instead. Interpreting serial CAC scores in patients on statins takes nuance and specialist interpretation. The absolute cardiovascular risk reduction from statin therapy holds steady even in the face of CAC progression.
Serial CAC Scanning: Should You Repeat the Test
How often to repeat a CAC scan isn’t fully settled in the literature. General framework: a single scan gives substantial prognostic information, but serial scanning — repeated at 3-5 year intervals — adds information about the rate of plaque progression, which carries its own prognostic value.
Rapid CAC progression (more than 25-30 Agatston units per year, or more than 100 units over 3-5 years) is independently associated with worse cardiovascular outcomes, even accounting for the absolute CAC level. Meaning someone who goes from CAC=50 to CAC=250 over four years has a more worrying trajectory than someone sitting at CAC=250 for four years without meaningful change.
The decision to repeat a scan should be guided by clinical context. For patients with CAC=0 at baseline, most guidelines support rescanning in 5-7 years to reassess if other risk factors show up. For patients with CAC in the 1-100 range on active lifestyle optimization, repeating at 3-5 years to assess progression — and the response to intervention — gives useful clinical data. For patients above 400 already on maximum therapy, serial scanning has less impact on clinical management, because treatment is already maxed out regardless of what the score does next.
The CAC Score Action Guide
The CAC Score Action Guide is a five-level framework translating CAC score results into specific clinical actions. Each level builds on the previous, calibrated to the risk information the CAC score provides.
- Level 0 — Score Zero: Celebrate, but don’t declare victory. A zero score in a person above 45 with no major risk factors supports deferring statin therapy and focusing on lifestyle optimization. Schedule a rescan in 5-7 years. Aggressively maintain whatever’s been protecting you: avoid smoking, manage blood pressure, keep blood glucose optimal, keep exercising. Very high LDL (above 190) or Lp(a) above 125 nmol/L? Maintain close monitoring even at CAC=0 — these patients can progress from zero to significant scores relatively fast.
- Level 1 — Score 1-100: Early plaque. Begin or confirm statin therapy (moderate-intensity typical in this range). Intensive lifestyle intervention: Mediterranean or DASH diet, 150+ minutes/week aerobic exercise, weight normalization. Address all modifiable risk factors. Order a complete lipid panel with ApoB and Lp(a) if not already done. Consider aspirin only after a bleeding risk assessment. Rescan in 3-5 years.
- Level 2 — Score 100-400: Significant plaque. Guideline care at this level means high-intensity statin therapy rather than moderate, with ezetimibe added when LDL stays above the threshold used for this risk category — below 70 mg/dL. Which agent, and at what strength, is a prescribing decision made with the treating physician. Blood pressure target below 130/80 mmHg. Intensive lifestyle: structured exercise combining aerobic and resistance training, anti-inflammatory diet, sleep optimization, stress management. Functional cardiac imaging (stress test) if symptomatic or if CAC sits toward the higher end of this range. See a cardiologist if not already under one. Aspirin often appropriate after bleeding risk review. Rescan in 3-4 years.
- Level 3 — Score Above 400: Severe plaque. Treat as secondary prevention equivalent. Maximum statin therapy plus ezetimibe. Consider PCSK9 inhibitor if ApoB stays above 70 mg/dL on maximum oral therapy. Refer to preventive cardiologist. Stress test to check for functional coronary obstruction. Full lifestyle overhaul: cardiac-rehab-style structured exercise, anti-inflammatory nutrition, comprehensive risk factor management. Aspirin typically indicated after bleeding risk assessment. Rescan in 2-3 years or as clinically guided.
- Level 4 — Rapid Progression on Serial Scanning: Regardless of absolute score, CAC increasing by more than 100 units over 3-5 years, or more than 30 units per year, despite apparently adequate therapy suggests inadequate risk factor control or an incomplete risk assessment somewhere. Comprehensive reassessment: full lipid panel with ApoB, Lp(a), inflammatory markers (hsCRP), glucose metabolism (fasting insulin, HbA1c), 24-hour blood pressure profile, sleep quality and sleep apnea screening, medication adherence review, detailed dietary and lifestyle audit. Consider additional therapies: PCSK9 inhibitor, omega-3 (Vascepa), colchicine for inflammation.
FAQ
- Where do I get a coronary calcium scan and how much does it cost? CAC scans are available at hospitals, radiology centers, and cardiac imaging centers. Cost ranges $75-$400 depending on location and insurance coverage. Many insurers cover it for appropriate indications; others require out-of-pocket payment. In the US, most states require a physician order. Some imaging centers offer direct patient access without a referral.
- Is the radiation exposure from a CAC scan dangerous? The dose (typically 1-3 mSv) is comparable to a mammogram, or roughly what the average person absorbs from natural background radiation over 6-12 months. The absolute cancer risk from this level is extremely small — estimated at less than 1 in 10,000 for an adult patient. The cardiovascular risk information the scan provides typically far outweighs this theoretical radiation risk in appropriate candidates.
- My CAC score went up on statin therapy — is my statin making things worse? Almost certainly not. As covered above, statins appear to stabilize soft plaques by promoting calcification within them, which raises the CAC score while reducing the risk those plaques rupture and cause a heart attack. An increased score on statins doesn’t signal treatment failure. One more reason serial CAC scanning in statin patients needs specialist interpretation.
- Can lifestyle changes reduce my CAC score? Substantial reductions in established coronary calcium are uncommon — once formed, calcium deposits are generally stable. What lifestyle change and medication can do is slow the rate of progression and reduce soft, non-calcified plaque. Very intensive lifestyle interventions (Ornish-style plant-based diet plus supervised exercise) have shown some cases of regression in small trials, but don’t expect that as a reliable outcome. The primary value of lifestyle and medication is preventing new plaque and stabilizing what’s already there.
- How is a CAC scan different from a coronary angiogram? A coronary angiogram (cardiac catheterization) is invasive — contrast dye injected directly into the coronary arteries, visualized under X-ray, identifying areas of significant narrowing (stenosis). It’s the gold standard for evaluating symptomatic coronary disease and determining whether stents or bypass surgery are needed. A CAC scan is non-invasive, cheaper, lower radiation, and measures something different — the burden of calcified atherosclerosis rather than the degree of narrowing. Complementary tools, used at different points in the evaluation pathway.
- What is Lp(a) and should I test it along with CAC? Lipoprotein(a) is a genetic variant of LDL carrying an additional protein (apolipoprotein(a)) that promotes thrombosis and atherosclerosis. Elevated Lp(a) — above 50 mg/dL or 125 nmol/L, affecting roughly 20% of the population — is a strong independent risk factor for cardiovascular disease. It should ideally be tested at least once in all adults, since it’s entirely genetically determined and doesn’t respond to diet or most medications. People with both elevated Lp(a) and a significant CAC score sit at particularly high risk and should be managed aggressively. See our guide on ApoB and heart risk markers for more detail.
- I have a CAC of zero but elevated LDL — do I still need a statin? For most people with CAC=0 and no other major risk factors, the weight of evidence supports minimal statin benefit near-to-medium term, and many guideline documents now support using CAC=0 as a “statin hold” trigger. That said, very high LDL (above 190 mg/dL, suggesting familial hypercholesterolemia), very high Lp(a), or strong family history of premature cardiovascular disease may argue for statin therapy even with a zero CAC, since these patients risk rapid progression. Best decided in consultation with a cardiologist specializing in prevention.
Integrating CAC Into Comprehensive Cardiovascular Risk Management
The CAC score isn’t a standalone diagnosis — it’s one data point in a comprehensive cardiovascular risk assessment, and its greatest value comes from how it integrates with other information to guide a cohesive management strategy. Understanding how CAC fits alongside lipid measurements, inflammatory markers, blood pressure, and lifestyle factors builds a more precise picture than any single test provides on its own.
ApoB and CAC complement each other in important ways. ApoB measures the atherogenic particle burden currently circulating in blood — the ongoing assault on the arterial wall. CAC measures the cumulative damage already deposited in the wall from years of that assault. A patient with high ApoB but zero CAC may carry aggressive lipid-driven risk that hasn’t yet shown up as visible calcification — a condition warranting intervention now to prevent what the ApoB predicts. A patient with CAC of 200 but relatively low ApoB has significant established disease from past lipid exposure, warranting aggressive management even if the ongoing assault has decreased. Together, they tell a fuller story: where you’ve been (CAC), what’s still happening to you (ApoB).
Lp(a) deserves specific mention in the CAC context. It’s a genetically determined risk factor affecting roughly 20% of the population that independently accelerates coronary atherosclerosis and currently can’t be lowered by any widely available medication (though PCSK9 inhibitors reduce Lp(a) by 20-30% as a secondary effect, and specific Lp(a)-targeted agents including pelacarsen are in late-stage trials). Patients with elevated Lp(a) often carry higher CAC scores for their age and other risk factors — knowing Lp(a) status adds important context to a CAC interpretation. A CAC of 150 in a patient with Lp(a) above 100 nmol/L carries a more concerning trajectory than the same score in a patient with normal Lp(a).
High-sensitivity CRP above 2 mg/L alongside a CAC score identifies patients whose risk combines structural plaque burden with active vascular inflammation — the highest-risk combination for plaque rupture and cardiovascular events. This inflammatory context supports more aggressive anti-inflammatory measures beyond standard lipid management: omega-3 fatty acids at 4g/day (the REDUCE-IT dose), anti-inflammatory dietary patterns, exercise intensification, and potentially low-dose colchicine, which demonstrated a 31% reduction in cardiovascular events in the COLCOT and LoDoCo2 trials among patients with coronary artery disease.
What to Discuss With Your Doctor Before and After a CAC Scan
The CAC scan delivers the most value as part of a structured clinical conversation, not when it’s ordered in isolation and the result reported without context. Preparing for both the pre-scan conversation and the post-result discussion maximizes what the test is actually worth clinically.
Before the scan: ask your physician to calculate your 10-year ASCVD risk score using the ACC/AHA Pooled Cohort Equations and explain where you fall in the treatment decision zones. In the “intermediate risk” zone (7.5-20%)? Clarify what specific result would support statin initiation versus deferral. Ask whether Lp(a) and ApoB are part of your current lipid assessment — if not, they should ideally get measured alongside the CAC for comprehensive risk stratification.
Understand what additional tests (stress test, cardiology referral) specific CAC results would trigger.
After the scan: if the result is zero, ask about the rescan interval appropriate for your risk profile (typically 5-7 years) and what risk factor changes would trigger earlier rescanning. Above 100, ask explicitly about the statin intensity appropriate for your score, whether ezetimibe should be added, and what blood pressure and glycemic targets apply to your risk category. Above 400, ask about referral to a preventive cardiologist and whether functional cardiac imaging is appropriate to check whether any identified plaque is causing significant obstruction.
The framing question that ties it together: “Based on my CAC score combined with my other risk factors, what’s my best current estimate of 10-year cardiovascular event risk, and how does that change the treatments or targets we should pursue?” A good preventive cardiologist can answer that precisely. A primary care physician can take a shot at it with risk calculator tools, and the answer shapes the intensity and composition of everything that follows.
The Athlete Paradox: High Exercise Volume and Coronary Calcium
One of the more surprising findings in cardiovascular research: extreme endurance athletes — marathon runners, ultramarathon competitors, long-career cyclists — sometimes show unexpectedly high coronary calcium scores despite excellent cardiovascular fitness. Several studies, including work by Jaime Rivas and colleagues, have found men who’ve done high-intensity endurance athletics for decades can accumulate coronary calcium at rates exceeding sedentary counterparts matched for traditional risk factors.
This paradox needs careful interpretation, and it doesn’t argue against exercise — athletes with high CAC scores still show dramatically lower cardiovascular event rates and mortality than their CAC scores alone would predict. The leading hypothesis: very-high-volume endurance exercise creates hemodynamic conditions (extremely high cardiac output, elevated blood pressure during exertion, repeated episodes of high shear stress) that accelerate coronary plaque calcification, even as the same exercise produces favorable plaque stabilization and endothelial adaptations that reduce how clinically dangerous the calcified plaque actually is.
Practical implication for athletes: a high CAC score in the context of a long endurance athletic career needs interpretation different from the same score in a sedentary individual. The calcification may represent a “calcification of the athletic coronary” — more stable, less vulnerable plaque — rather than the same atherosclerotic process running in a non-athlete. That said, traditional cardiovascular risk factors (ApoB, Lp(a), blood pressure, metabolic health) still need addressing in athletic populations, because risk factors act on the same underlying plaque biology in athletes as in sedentary people, even if the exercise-adapted vascular environment offers more protection. An athlete with CAC of 200 and elevated ApoB and elevated Lp(a) warrants aggressive lipid management, regardless of fitness level.
Tom’s story isn’t unusual in its outcome once the problem got identified — it’s unusual in that the problem got identified at all. Most men in his position never get a CAC scan. They get risk factor measurements that look acceptable, get reassurance, and keep accumulating coronary calcium until the accumulation becomes either a symptom or an event. The ten-minute, $200 test that could reclassify their risk and change their treatment doesn’t get ordered, because it isn’t part of the standard workflow.
Lifestyle Changes That Matter Most After a High CAC Score
Receiving a CAC score above 100 or 400 can be a significant psychological event — it converts abstract statistical risk into concrete, visible evidence of disease already sitting in the coronary arteries. Some patients find that motivating. Others find it frightening. The most productive response channels the information into action on the specific modifiable risk factors that’ll have the greatest impact on preventing the plaque from causing an event.
Statin therapy and blood pressure control are the pharmacological priorities most strongly supported by evidence for patients with significant coronary calcium. But the lifestyle factors that matter most for slowing CAC progression and reducing event risk in patients with established plaque are the same factors that prevent initial plaque formation in the first place: maintaining cardiorespiratory fitness (exercise doesn’t reverse calcium deposits, but it dramatically cuts the clinical risk of those deposits by stabilizing plaque and improving endothelial function around it), maintaining non-smoking status absolutely (smoking keeps accelerating plaque vulnerability even in patients on maximum medical therapy), achieving optimal metabolic health (fasting insulin below 7, HbA1c below 5.5%), and aggressively managing blood pressure below 130/80 mmHg.
Dietary anti-inflammatory measures matter particularly after a high CAC score. The Mediterranean dietary pattern — high in vegetables, legumes, fatty fish, olive oil, nuts, low in ultra-processed foods and refined carbohydrates — was shown in the PREDIMED trial to reduce cardiovascular events by roughly 30% in high-risk patients, attributed to anti-inflammatory, antiplatelet, and lipid-modifying mechanisms working together. The Lyon Diet Heart Study found Mediterranean diet intervention cut recurrent cardiovascular events by an extraordinary 65% in post-myocardial infarction patients. No statin trial gets anywhere near that magnitude of relative risk reduction. Worth sitting with that.
Sleep optimization deserves specific mention in post-CAC management. Sleep apnea — causing intermittent hypoxia and autonomic nervous system activation throughout the night — is strongly associated with accelerated cardiovascular disease, and it’s dramatically underdiagnosed. Any patient with a high CAC score and symptoms suggesting sleep apnea (snoring, witnessed apneas, unrefreshing sleep, morning headaches) should get a sleep study. Treating sleep apnea reduces blood pressure, reduces cardiac arrhythmia risk, and reduces inflammatory markers — all mechanisms relevant to slowing coronary artery disease progression.
The CAC scan isn’t a perfect tool. It misses soft plaque. It requires radiation. It can complicate the statin conversation with paradoxical progression on treatment. And interpreting the result takes clinical context — the same score means something different in a 45-year-old versus a 65-year-old, in an extreme endurance athlete versus a sedentary executive, in a patient with elevated Lp(a) versus one with normal lipids. The value of the CAC scan isn’t just the number it produces but the conversation it enables — the shift from statistical population risk to individual biological reality. Tom didn’t need to guess whether his acceptable-looking risk factor profile meant his arteries were safe. He found out directly. The scan told the truth his standard labs had been obscuring for a decade. And that truth, delivered before an event rather than after one, turned out to be the most important thing his healthcare encounters had ever given him. As a single test for understanding the actual state of your coronary arteries — not the estimated state based on risk factors, the actual biological reality — it’s unmatched among the non-invasive tools currently available. For the comprehensive cardiovascular prevention framework, see our guides on heart health prevention for men and ApoB as a heart risk marker.
The Practical Framework: Applying Coronary Calcium Score Scan In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map